12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tykerb: Phase III data

Researchers at the German Breast Group and colleagues reported data from the open-label, German Phase III GeparQuinto trial in 615 evaluable previously untreated HER2-positive advanced breast cancer patients showing that a significantly greater proportion of patients receiving Herceptin trastuzumab plus chemotherapy (epirubicin plus cyclophosphamide and docetaxel) achieved a pCR, the...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >